Cardiology
RSSArticles
-
Clinical Briefs in Primary Care supplement
-
Abstract & Commentary: Do Macrolide Antibiotics Improve Survival in Acute Lung Injury?
This is a report of a secondary analysis of data from the original Acute Respiratory Distress Syndrome (ARDS) Network low-tidal-volume study, which demonstrated improved survival with ventilator tidal volumes of 6 (vs 12) mL/kg predicted body weight in patients meeting the American-European consensus definition of acute lung injury (ALI) or ARDS. -
Critical Care Clinicians Require Critical Communication Skills
The purpose of this article was to apply aviation communication principles and strategies to the field of critical care medicine, particularly crisis communication situations. -
Abstract & Commentary: Treating VAP: The Importance of Getting Initial Antibiotic Coverage Right
This study was a secondary analysis of data from an earlier randomized clinical trial comparing one antibiotic vs two (meropenem alone or meropenem plus ciprofloxacin) as early empiric therapy for ventilator-associated pneumonia (VAP). -
Physician Protect Thyself (and Your Patients and Coworkers)!
The advisory committee on immunization practices (ACIP) of the CDC has updated their recommendations for immunization of health care providers (HCP) against communicable infectious diseases. -
Clinical Briefs By Louis Kuritzky, MD
Between statin head-to-head trials are uncommon. -
Internal Medicine Alert - Full January 29, 2012 Issue in PDF
-
Early Referral of the Chronic Kidney Disease Patient is Good Practice
A meta-analysis demonstrates that earlier nephrologist referral leads to reduced mortality and hospitalization as well as better preparation and dialysis access placement. -
Daytime Sleepiness as a Stroke and Cardiac Risk Factor
Excessive daytime sleepiness appears to be an important risk factor for stroke. It is unknown whether this is related to obstructive sleep apnea or other mechanisms. -
Clobazam Tablets (ONFI™) CIV
A new benzodiazepine anticonvulsant was recently approved for the treatment of a difficult-to-treat childhood epilepsy (Lennox-Gastaut syndrome [LGS]). Clobazam is manufactured by Catalent Pharma Solutions and marketed as ONFI.